The proteomic technology will be applied to biomarker discovery, target discovery and validation, and companion diagnostics.
SomaLogic CEO Larry Gold said their technology would help address the issues in drug discovery and development currently faced by biopharmaceutical companies.
The terms of the deal, however, have not been disclosed.